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AntioxidantBackground: Antioxidants can be used as adjuvant treatment of polycystic ovary syndrome (PCOS).
Melatonin (MT) is one of the antioxidant that is used nowadays.
Objective: In this study, the effect of MT on the histological changes of ovary in the experimental model of
polycystic ovary syndrome is investigated.
Methods: In this study 30 immature female NMRI mice were divided into 5 groups including: (1) control
group received distilled water, (2) received a dose of 10 mg/kg MT for 5 days, (3) received
Dehydroepiandrostenedione (DHEA) at a dose of 6 mg/kg for 20 days to induce PCOS, (4) after induction
of PCOS received MT at a dose of 10 mg/kg for 5 days, and (5) received 6 mg/kg DHEA and 10 mg/kg MT
for 20 days simultaneously.
Results: The evaluation of ovarian tissue characteristics such as the granulosa layer, theca, number and
diameter of cysts and follicles was performed. PCOS caused a significant reduction in the number of antral
follicles and corpus luteum and an increase in the number of primordial, primary, pre-antral and cystic
follicles in comparison with the control group (P < 0.05). Moreover, MT resulted in a significant increase
in the granulosa layer thickness in group 4 (P < 0.001), and group 5 (P = 0.001) and a significant reduction
in the thickness of theca layer between groups 4 and 5 compared with group 3 (P < 0.001).
Conclusion: These findings indicate that MT have a protective effects on polycystic ovary damages
induced by DHEA, although the mechanism is unclear. It is likely that this is happening by reducing
oxidative damage.
 2017 Middle East Fertility Society. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Polycystic ovary syndrome (PCOS) is the most common cause of
infertility (20% of infertile couples) and 6–8% of women suffer from
this endocrine disorder in their reproductive age; this disorder was
discovered by Stein and Leventhal for the first time in 1935 [1,2].
Several studies have shown that this syndrome can cause histolog-
ical abnormalities such as bilateral ovarian enlargement of more
than 10 mm, presence of more than 12 follicles of less than
10 mm size in the central dense stroma, increasing the thickness
of the follicular sheath and ovarian stroma due to increase in
angiogenesis, vasculogenesis, ovarian blood flow and, conse-
quently, reduction or chronic anovulation and infertility [3,4].Women with polycystic ovary syndrome have a wide range of clin-
ical symptoms, but usually they seek medical advice due to three
disorders that include irregular menstruation, infertility and symp-
toms associated with an increase in androgens such as hirsutism
and acne [5]. Various treatment methods have been proposed for
polycystic ovary syndrome, such as changing lifestyle, surgery
and taking medication. Now the most recognized way of treatment
is using medications such as clomiphene citrate, metformin, Letro-
zole and Tamoxifen [6]. Considering the side effects of these med-
ications, identification and preparation of alternative medicine is
important. However, extensive research to find new treatments
have shown that oxidative stress, inflammation and activation of
endothelial cells in the ovary plays an important role in the patho-
genesis of PCOS and it leads to the development of atherosclerotic
lesions in the ovaries. Therefore, a positive correlation between the
reduction of oxidative stress and increased oocyte maturation in
women with PCOS and infertility has been found. It seems that
antioxidants reduce oxidative stress in different ways and as aodel in
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is one of the antioxidants that are in focal attention nowadays. MT
and its metabolites are potent antioxidants that remove free radi-
cals and increase the expression of several antioxidant enzymes
[8]. Consuming MT in laboratory mice protects cells against oxida-
tive damage. In fact, it reduces oxidative stress in various ways [9].
MT, N-acetyl-5-methoxy-tryptamine which is a lipophilic Indola-
mine is synthesized mainly by the pineal gland. MT, in a circadian
rhythm, is secreted during the night with high levels in all species.
In mammals, including humans, MT rhythm is produced by an
endogenous circadian clock in the suprachiasmatic nucleus and it
impacts the hypothalamus-pituitary-gonad axis [10]. MT receptors
have been identified in the nerve cells of the hypothalamus, which
governs the release of gonadotropins pituitary gland, in the pitu-
itary gland, in both male and female gonads and other reproductive
organs [11–13]. In mammals, MT can affect reproductive function
through the activation of the receptors in hypothalamic hypophy-
seal gonadal axis [14]. MT is also found in the fluid of the ovarian
follicles [15]. The Increase of MT in follicular fluid leads to a lower
incidence of oxidative damage inside the follicle. Reducing oxida-
tive stress increases the fertilization and pregnancy in women
who could not be pregnant due to poor quality of oocytes [11].
MT receptor in rat, mouse and pig ovary cells has been found which
suggests that it‘s has a direct effect on oocyte maturation [11,13].
Recently, In vitro studies have shown that MT plays an important
role in optimal egg development and ovulation, and has a positive
impact on early embryonic development [16]. Interestingly, MT
concentration in large follicles is more than small follicles. High
levels of MT in large follicles are likely to protect the granulosa
cells of radicals that are induced during ovulation [17]. Considering
the aforementioned issues, the inhibitory effect of MT on pituitary
gonadotropin secretion and inhibiting intra follicular oxidative
stress, and considering the fact that no report was found up to con-
ducting this study, the effect of MT on the histological changes in
induced polycystic ovary syndrome was analyzed.2. Materials and methods
In this study, thirty NMRI rats which were 14 days old were
used. To adapt animals, they were held in their cages for one week
in laboratory conditions including 2 ± 21 C, 12 h periods of light,
free consumption of food and water and good ventilation. Then,
the mice were weighed and randomly divided into 5 groups (each
group consisted of 6 mice). Control group: the mice in this group
received distilled water intraperitoneally as MT solvent. The treat-
ment control groups: to study the effects of MT on changes in the
ovaries and the ovulation power of oocytes under normal circum-
stances, this group received 10 mg/kg MT intraperitoneally for
5 days. Disease group: In order to induce PCOS, this group received
Dehydroepiandrostenedione (DHEA) (6 mg/kg) for 20 days
intraperitoneally. Treatment group: after inducing polycystic ovar-
ian syndrome on mice in this group, they were treated by MT
intraperitoneally for 5 days. The prevention group: in order to
study the effects of MT in the prevention of inducing polycystic
ovary syndrome, mice in this group received at the same time
6 mg/kg DHEA and 10 mg/kg MT for 20 days. At the end of the
experiment mice were weighed and killed by cervical dislocation
and their abdomen was opened under sterile conditions and their
ovaries were removed for morphology/morphometry study.2.1. Polycystic ovary syndrome induction method
To induce phenotype of Polycystic ovary syndrome in immature
mice (approximately 22–21 days old), they were treated for
20 days with daily injections of DHEA at a dose of 6 mg/kg of bodyPlease cite this article in press as: M. Ahmadi et al., The effect of Melatonin on h
mice, Middle East Fertil Soc J (2017), http://dx.doi.org/10.1016/j.mefs.2017.03.weight intraperitoneally [18]. In order to confirm the induction of
PCOS, three mice were sacrificed and their ovaries were separated
from the spiral oviduct tube. Then, excessive fat was carefully dis-
sected without damaging ovarian tissue under loop and ovaries
were put inside fixative in order to do histotechnique procedure
[19].
2.2. Administration of MT
MT was injected intraperitoneally for 5 days, everyday 10 mg/
kg body weight. Duration and dose of MT were decided based on
the previous studies conducted on rats and mice [20,21].
2.3. Histological analysis
Both mice ovaries were removed for histological examination.
After fixation of tissue samples in Buin solution for 16–14 h, the
samples were dehydrated with alcohol solutions with rising levels
20–100% in each for 45 min to one hour, and then were clarified in
xylene alcohol (50:50), xylene (three times) and embedded in
paraffin. The samples were cut with a microtome 5 lm diameter
and sections were placed on slides. After Deparaffmization of sec-
tions and their yielding with alcohol solutions with lowering
levels, they were painted by hematoxilina and they were differen-
tiated with acid-alcohol solution and then they were stained [22].
In the final stage, the tissue sections taken from the ovaries were
observed under an optical microscope with a magnification of 40
and different follicular groups were counted. Moreover, the thick-
ness of antral follicles theca layer and granulosa were measured. In
order to evaluate changes in ovarian tissue, ovarian structures
were categorized into 6 groups based on morphology: Primordial
follicles (PRIF), Primary follicles (PF), Preantral follicles (PAF),
Antral follicles (AF), Cystic follicles (CF) and Corpus luteum (CL)
and their changes in the ovaries were examined [23].
2.4. Statistical analysis
Kolmogorov-Smirnov test, Kruskal Wallis test, ANOVA test,
Levene test, Tukey test and SPSS version 20 were used for statisti-
cal analysis of the data. P value less than 0.05 was considered
significant.3. Results
By analyzing the histological morphology of ovaries in the con-
trol group and the control treatment group different follicles were
seen including graafian follicles with a thick layer of granulosa cells
and corpus luteum. A number of cystic follicles with a very thin
layer of granulosa which is the property of cystic follicles were
seen in the ovaries of the disease group. In this group, only a few
corpus luteum that indicates ovulation were observed. Therefore,
based on the observations of ovarian tissue, injecting DHEA to mice
for 20 days resulted in creating cystic follicles and a decrease in the
number of antral follicles and corpus luteum and anovulation or
very low ovulation (due to the reduction in the number of corpus
luteum) in this group. Morphological studies in disease treatment
group compared with disease group showed that MT during 5 days
had resulted in an increase in the number of follicles, reducing the
number of cystic follicles (3 ± 1.41 vs. 33.83 ± 1.60) and increase in
the number of CL (7.16 ± 2.31 vs. 0.16 ± 0.40). Also, injecting MT
with DHEA at the same time in the prevention group compared
with disease group showed a reduction in the number of cystic fol-
licles (5.66 ± 1.63 vs. 33.83 ± 1.60) and an increase in the number
of corpus luteum (5 ± 1.41 In contrast, 0.16 ± 0.40) (Fig. 1).
10 mg/kg MT per day did not create a significant change on theistological changes of ovary in induced polycystic ovary syndrome model in
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Fig. 1. Photomicrograph of ovaries in different studied groups (Hematoxilina and Eosin staining). (a) ovarian section of control group with healthy growing follicles and a
corpus luteum (*) (magnification: 40). (b) boxed area in a, shows the graafian follicle in the control group (magnification:  100). (c) ovarian section of treatment group
(magnification: 40). (d) boxed area in c, shows the graafian follicle in the treatment group (magnification: 100). (e) ovarian section of disease group with several cyst-like
follicles (#) (magnification:  40). (f) boxed area in e, represents different follicles in the disease group (magnification: 100). (g) ovarian section of disease treatment group
(magnification: 40). (h) boxed area in g, observing various follicles along with CL in disease treatment group (magnification: 100). (i) ovarian section of prevention group
(magnification:40). (j) boxed area in i, observing various follicles along with CL in prevention group (magnification:100). Arrow showing granulosa cell layer, double-sided
arrow showing a compact theca cell layer. Scale bar 100 lm.
M. Ahmadi et al. /Middle East Fertility Society Journal xxx (2017) xxx–xxx 3changes of the ovary tissues in the treatment control group com-
pared with the control group, (Table 1). Using DHEA in order to cre-
ate models of polycystic ovary syndrome in laboratory mice
reduced the number of AF and CL follicles and increased the num-
ber of PRIF, PF, PAF and cystic follicles, compared with a control
group. These changes were statistically significant (P < 0.05). TheTable 1
Comparison of index numbers of the studied variables based on the studied groups.
Number of variables Group 1 Group 2 Gr
Primordial follicles 24.16 ± 1.47 29.66 ± 1.03 27
Primary follicles 9 ± 1.89 10.16 ± 2.04 18
Pre-antral follicles 20 ± 3.03 28.66 ± 2.25 35
Antral follicles* 7.66 ± 2.16 8.16 ± 2.31 6.
Cystic folliclesy 0 0.16 ± 0.04 33
Corpus luteum 11.83 ± 1.47 13 ± 1.41 0.
Regarding primordial follicles the difference between group (3, 5) P < 0.001.
Regarding primary follicles the difference between group (3, 4) and (3, 5) P < 0.001.
Regarding antral follicles the difference between group (3, 4) P = 0.003, between group
Regarding cystic follicles the difference between group (3, 4) and (3, 5) P < 0.001.
Regarding corpus luteum the difference between group (3, 4) and (3, 5) P < 0.001.
* The presented amounts with SD ± Mean (Variance analysis and Tukey).
y The presented amounts with Kruskal Wallis.
Please cite this article in press as: M. Ahmadi et al., The effect of Melatonin on hi
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ment group showed a significant decrease compared to the preven-
tion group, while the average number of CL in the disease
treatment and prevention group had increase compared with the
disease group (P < 0.05). Moreover, the number of PRIF, PAF and
CL follicles in the prevention group had significantly decreasedoup 3 Group 4 Group 5 P value
.66 ± 1.36 27.16 ± 3.06 8.33 ± 2.06 0.028
.33 ± 1.63 5.83 ± 1.47 7.16 ± 1.16 0.782
± 2 25.33 ± 1.75 21.16 ± 1.32 0.341
33 ± 1.86 2.66 ± 1.47 4 ± 1.26 0.673
/83 ± 1.60 3 ± 1.41 5.66 ± 1.63 0/005
16 ± 0.40 7.16 ± 2.31 5 ± 1.41 0.060
(3, 5) P = 0.046.
stological changes of ovary in induced polycystic ovary syndrome model in
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Fig. 3. The morphometry of theca layer thickness in various groups’ ovary that had
a significant decrease in ovary of treatment and prevention of disease group
compared with disease group (6 = n) (mean ± SD). P < 0.001 *.
4 M. Ahmadi et al. /Middle East Fertility Society Journal xxx (2017) xxx–xxxcompared to the disease treatment group, while the average num-
ber of cystic follicles in the prevention group showed an increase
compared to the disease treatment group (P < 0.05). In measuring
the diameter of follicles in the ovaries of different groups, signifi-
cant differences were observed between the groups. A significant
increase in the size of the follicles were observed between the con-
trol group (P < 0.001), and the disease group which is due to cysts.
A significant reduction in the size of diameter of follicles in the
treatment group (P < 0.001) and prevention (P = 0.016) t was
observed compared with the disease group (Fig. 2). Theca layer
measurements in the 5 groups showed a significant increase in
the thickness of the theca between the control and disease group
(P < 0.001). However, a significant decrease (P < 0.001) in the thick-
ness of theca layer between disease group and the treatment and
prevention of disease groups was observed (Fig. 3). In measuring
the granulosa thickness layer in the 5 groups a significant decrease
(P < 0.001) between disease and control group was seen and a sig-
nificant increase between disease group and the treatment group
(P < 0.001) and the prevention group (P = 0.001) was observed
(Fig. 4).Fig. 4. The morphometry of thickness of granulosa layer in different groups’ ovary
that a significant increase in ovary of treatment and prevention of disease group is
seen compared with disease group (6 = n) (mean ± SD). P < 0.001 *, P = 0.001 **.4. Discussion
In this study, the phenotype polycystic ovary syndrome was
created and the effects of MT on the development of the follicular
growth and improvement of this disease on the basis of morpho-
logical and morphometric observations were investigated. Also,
the effect of administering MT alone and in combination with
DHEA on the ovarian tissue was examined. In order to induce PCOS
phenotype, a variety of hormonal and non-hormonal methods can
be used such as: Letrozole [24], Estradiol Valerate [25], Testos-
terone Propionate [13], and Testosterone Enanthate [26]. More-
over, it is possible to induce PCOS through exposing the
laboratory animal to uniform light [27]. In some studies transgenic
mice is used to induce PCOS [28]. One of the advantages of animal
models that are created by androgens is that the outer androgens
lead to lasting damage to ovarian tissue and reparation of Hallmark
symptoms of PCOS in these models [18]. In this study, considering
the positive results of Sander et al. [29] in using DHEA to induce
phenotype of PCOS, this androgen was used. Therefore, the current
study showed that a 6 mg/kg dose of DHEA intraperitoneally in
mice, leads to changes in the follicular and morphological changes
of ovary. MT as the most important epiphyseal gland secretion is a
highly effective antioxidant and neutralizing free radicals [30]. Due
to its small size and high lipophilic properties of MT it crosses the
cell membrane very easily and disperses around the cell [31]. ItsFig. 2. The morphometry of follicular diameter in the ovary different groups’ that
had a significant reduction in treatment and prevention of disease group compared
with disease group (n = 6) (mean ± SD). P < 0.001 *, P = 0.016 **.
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mice, Middle East Fertil Soc J (2017), http://dx.doi.org/10.1016/j.mefs.2017.03.concentration is very high in the cell nucleus and keeps the struc-
ture of DNA against damaging agents [30]. The study showed that
taking 10 mg/kg MT concurrently with DHEA for 5 days would
decrease the adverse effects of DHEA on the ovaries. Therefore, it
seems that the improvement in the treatment process of ovulation
in the fifth group (prevention group) by MT and DHEA is due to the
antioxidant properties of MT. Similarly, Mohammad Ghasemi et al.
showed in a study that taking MT in mice treated with nicotine
reduces damage to the ovary and it protects ovarian folliculogene-
sis [32]. Thus, it seems that MT has reduced the side effects of
DHEA in this study. MT dosage in this study was based on similar
studies of Atessahin, Guneli and Mohammadghasemi on mice
[21,32,33]. The result of qualitative study in the treatment and pre-
vention groups corresponds to the symptoms of PCOS in this group.
It is likely that these changes and the process of ovulation preser-
vation with better maturity in the fourth and fifth group in com-
parison with the third group can be as a result of the following
mechanisms: (i) strong antioxidant properties of MT; as it can acti-
vate the activity or gene expression of antioxidant enzymes such as
superoxide dismutase, glutathione reductase and glutathione per-
oxidase [30]. (ii) Anti-apoptotic properties of MT; its effect has
been shown on different tissues in several experiments [21,32].
(iii) Anti-proliferative properties of MT [32], previous studies in
mice have shown that there is an inverse relationship between
MT and GnRH receptor and MT decreases the secretion of LH
and FSH [34]. Moreover, previous reports indicated that MT hadistological changes of ovary in induced polycystic ovary syndrome model in
009
M. Ahmadi et al. /Middle East Fertility Society Journal xxx (2017) xxx–xxx 5anti-proliferative effects both on the productive cells [35] and
other cells [36,37]. However, the above mechanisms are not proved
and to prove them, further studies regarding cellular, molecular
and immunohistochemistry and endocrinology is required.5. Conclusion
In summary, the present study showed that injecting 6 mg/kg
DHEA intraperitoneally, leads to changes in morphology and num-
ber of ovarian follicles to induce the polycystic ovary syndrome.
Injecting 10 mg/kg MT intraperitoneally for 5 days during and after
the induction of PCOS phenotype had significantly decreased
adverse changes of DHEA in the morphology of ovary and consid-
ering their antioxidant properties it had an effective protective
effect on the natural structure of ovary of mice. This study suggests
that MT may be effective for clinical use in ovarian failure to pre-
vent the development of PCOS and also after suffering from this
syndrome.Conflict of interest
The authors declare no conflict of interest.
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